Adlai Nortye (NASDAQ:ANL) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Adlai Nortye from “hold” to “buy,” while the broader analyst consensus is “Moderate Buy,” with five Buy ratings and one Sell rating.
• Analysts’ average price target is $24.25; recent targets include $22 from JonesTrading and $32 from Oppenheimer.
• ANL opened at $13.70, up from its 50-day average of $11.78, while hedge funds and institutional investors own approximately 35.21% of the stock.

Adlai Nortye (NASDAQ:ANL - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other research analysts have also weighed in on the company. JonesTrading initiated coverage on Adlai Nortye in a research report on Thursday, May 14th. They set a "buy" rating and a $22.00 price target on the stock. Oppenheimer assumed coverage on Adlai Nortye in a research report on Thursday, May 28th. They set an "outperform" rating and a $32.00 price objective for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. Finally, Cantor Fitzgerald assumed coverage on Adlai Nortye in a report on Monday, June 22nd. They issued an "overweight" rating on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.25.

Adlai Nortye Trading Down 0.1%

ANL opened at $13.70 on Friday. The stock has a fifty day moving average of $11.78 and a 200-day moving average of $11.06. Adlai Nortye has a 12-month low of $0.88 and a 12-month high of $17.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55.

Hedge Funds Weigh In On Adlai Nortye

Institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP acquired a new stake in Adlai Nortye in the second quarter valued at approximately $9,145,000. Boone Capital Management LLC acquired a new position in shares of Adlai Nortye during the 2nd quarter worth $2,971,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye during the 1st quarter valued at $816,000. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye during the 1st quarter valued at $1,140,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Adlai Nortye in the 1st quarter valued at $457,000. 35.21% of the stock is currently owned by hedge funds and other institutional investors.

About Adlai Nortye

Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source